2016 American Transplant Congress
Evaluating the Influence of Liver Donor and Recipient Race on Tacrolimus Dose Requirements.
Einstein Medical Center, Philadelphia, PA.
Background: The majority of liver transplant recipients (LTR) receive tacrolimus (TAC) to prevent allograft rejection. Early establishment of therapeutic levels is imperative to efficacy. Several…2016 American Transplant Congress
Nuclear Factor of Activated T-Cells Post-Renal Transplant.
Background: Nuclear Factor of Activated T-cells (NFAT1) is a transcription factor regulating the expression of key targets involved with cellular immune function. Calcineurin is a…2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…2016 American Transplant Congress
Late Renal Allograft Rejection Is Predicted by High Intrapatient Variability of Tacrolimus Levels.
Imperial College Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom.
IntroductionNonadherence to immunosuppressive medication is associated with rejection and graft loss. We have previously shown that intrapatient variability (IPV) of tacrolimus trough levels between 6-12…2016 American Transplant Congress
Factors and Outcomes Associated with Daptomycin Non-Susceptible Enterococcal Infections in Solid Organ Transplant Recipients.
Background: Daptomycin non-susceptible enterococcal (DNSE) infections are associated with poor outcomes. Information regarding factors and outcomes of DNSE in solid organ transplant (SOT) recipients (SOTR)…2016 American Transplant Congress
Plasma Alemtuzumab Levels Show Great Interpatient Variability, but Are Not Associated with Late Acute Rejection in Simultaneous Pancreas-Kidney Recipients.
Introduction: Alemtuzumab induction followed by a steroid-free, tacrolimus (Tac) and mycophenolate mofetil (MMF) based regimen effectively prevented acute rejection after simultaneous pancreas-kidney transplantation (SPKT). Acute…2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…2016 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…2015 American Transplant Congress
Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression was evaluated in clinical outcomes as well as protocol biopsies findings and donor…2015 American Transplant Congress
Pharmacogenomic Predictors of Acute Rejection in Kidney Transplant Recipients Identified Using a DNA Biobank Linked to Electronic Medical Records
Purpose: Risk for acute rejection (AR) complicating transplant immunosuppression may be affected by frequent variants in pharmacogenes. Using a DNA biobank linked to electronic medical…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- Next Page »